Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	Χ	Χ	Х	Х	Χ	Χ	Χ

# Continuous Glucose Monitoring Devices (CGMs)[CCC+ MCD only]

Override(s)	Approval Duration		
Prior Authorization	Receiver: One time		
	Sensors and transmitters: 1 year		

Continuous Glucose Monitoring Devices (CGMs) – including sensor, transmitter, receiver	Comments
Dexcom Product Line	Preferred
Freestyle Libre Product Line	
Eversense Product Line	Non-Preferred
Medtronic Product Lines for the following products:  • Enlite sensors  • Guardian (monitors, receivers, sensors, transmitters)  • Minimed Guardian sensor  • Sof-sensor	

## **APPROVAL CRITERIA**

CRX-ALL-0592-20

## **Step Therapy for non-preferred agents**

Requests for non-preferred continuous glucose monitoring devices and supplies (receiver, transmitter, sensor) must meet the following criteria:

- I. Individual has had a trial (medication samples/coupons/discount cards are excluded from consideration as a trial) and inadequate response or intolerance of one preferred continuous glucose monitor (Dexcom Product Line or Freestyle Libre Product Line); **OR**
- II. Individual utilized an insulin pump that is only compatible with a non-preferred continuous glucose monitor.

PAGE 1 of 2 07/01/2020 New Program Date 07/01/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	Χ	Χ	Х	Х	Χ	Χ	Χ

# **Prior Authorization for all agents**

Requests for continuous glucose monitoring devices may be approved when the following criteria are met:

- I. Individuals with Type I diabetes, no age limitations:
  - A. Inadequate glycemic control despite self-monitoring at least 4 x/day, with fasting glucose >150; **AND**
  - B. Recurring episodes of severe hypoglycemia <50 mg/dl **or** hypoglycemic unawareness; **AND**
  - C. Insulin injections are required three (3) or more times per day or an insulin pump is used for maintenance of blood sugar control.

## OR

- II. Individuals with Type 2 diabetes, age >16:
  - A. Inadequate glycemic control despite self-monitoring at least 4 x/day, with fasting glucose >150; **AND**
  - B. Recurring episodes of severe hypoglycemia <50 mg/dl **or** hypoglycemic unawareness; **AND**
  - C. Insulin injections are required three (3) or more times per day or an insulin pump is used for maintenance of blood sugar control.

### OR

- III. Pregnant individuals with Type 1 or Type 2 diabetes who are injecting insulin:
  - A. Inadequate glycemic control despite self-monitoring at least 4 x/day, with fasting glucose >150; **AND**
  - B. Recurring episodes of severe hypoglycemia <50 mg/dl **or** hypoglycemic unawareness; **AND**
  - C. Insulin injections are required three (3) or more times per day or an insulin pump is used for maintenance of blood sugar control.

## **Key References**:

Commonwealth of Virginia's *State Plan for Medical Assistance* (Medicaid), Durable Medical Equipment and Supplies Manual, Chapter IV, Covered Services and Limitations, p.27, rev. 01/23/20